Home World News Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among... World News Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC By Ogkologos - July 7, 2025 834 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-689 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR FDA Approves Nivolumab and Hyaluronidase-nvhy for Subcutaneous Injection February 7, 2025 A Combination of Avutometinib Plus Defactinib Results in Clinically Meaningful Benefit... August 5, 2025 GreaterGood Charities Provides Supplies and Support to People and Pets After... December 17, 2021 What the Budget 2021 means for research October 29, 2021 Load more HOT NEWS NHS England Lung Cancer Screening Programme Demonstrates that it is Feasible and Scalable... 3rd Grader Writes Note for Teacher Battling Breast Cancer to Read... Breaking News: The Healthcare Marketplace Re-opens TODAY! Celebrating 10 years of partnership with NIVEA Sun
